PTC Therapeutics, Inc. Repayments of Convertible Debt
PTC Therapeutics, Inc. (PTCT) reported Repayments of Convertible Debt of $327.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-07-30
- PTC Therapeutics, Inc. repayments of convertible debt for the quarter ending 2022-12-31 was $0.00.
- PTC Therapeutics, Inc. repayments of convertible debt for fiscal 2022 was $150.00M.
- PTC Therapeutics, Inc. repayments of convertible debt for fiscal 2020 was $28.33M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $327.89M 10-Q · filed 2026-07-30 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $150.00M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $150.00M 10-Q · filed 2023-10-26 | |||
| 2020-12-31 | $28.33M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |